SPRYCEL

Compare SPRYCEL  to:
Compare
Compare

Generic Name for SPRYCEL

Dasatinib 20mg, 50mg, 70mg; 100mg; tabs.

Legal Classification:

Rx

Pharmacological Class for SPRYCEL

Tyrosine kinase inhibitor.

Manufacturer of SPRYCEL

Bristol-Myers Squibb

Indications for SPRYCEL

Chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.

Adult dose for SPRYCEL

Swallow whole. ≥18yrs: Chronic phase CML: 100mg once daily. Doses of up to 140mg once daily have been used. Accelerated phase CML, myeloid or lymphoid blast CML, Ph+ ALL: 140mg once daily. Doses of up to 180mg once daily have been used. Concomitant CYP3A4 inhibitors (see Interactions): consider reducing dose. Concomitant CYP3A4 inducers (see Interactions): consider increasing dose. See literature for dose adjustments with toxicity.

Children's dosing for SPRYCEL

<18yrs: not recommended.

Warnings/Precautions for SPRYCEL

History of QT prolongation. Proarrhythmic conditions. Cumulative high-dose anthracycline therapy. Hypokalemia, hypomagnesemia; correct electrolyte imbalances before starting therapy. Monitor for pleural effusions. Obtain CBCs weekly for the first 2 months, then monthly thereafter. Hepatic impairment. Pregnancy (Cat.D; use adequate contraception); nursing mothers: not recommended.

Interactions for SPRYCEL

Avoid potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin, voriconazole), grapefruit juice. May be antagonized by CYP3A4 inducers (eg, dexamethasone, phenytoin, carbamazepine, rifampin, rifabutin, phenobarbital); St. John's wort: not recommended. Separate dosing of antacids by at least 2 hours; H2 blockers, proton pump inhibitors: not recommended. May potentiate drugs metabolized by CYP3A4 (eg, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, ergot alkaloids). Caution with concomitant anticoagulants or drugs that inhibit platelet function.

Adverse Reactions for SPRYCEL

Myelosuppression (eg, thrombocytopenia, neutropenia, anemia), fluid retention (eg, ascites, edema, pleural and pericardial effusions), GI upset, headache, dyspnea, rash, fatigue, hemorrhage (eg, CNS, GI); QT prolongation.

How is SPRYCEL supplied?

Tabs 20mg, 50mg, 70mg—60
100mg—30

Related Disease:

Leukemia, acute lymphoblastic
Leukemia, chronic myelogenous
Neoplasms

Related Resources

FDA grants priority review to Sprycel for newly diagnosed chronic myeloid leukemia (CML) in chronic phase

July 12, 2010

Bristol-Myers Squibb and Otsuka announced that the supplemental New Drug Application (sNDA) for Sprycel (dasatinib) for the treatment of adult patients with newly diagnosed chronic myeloid leukemia (CML) in chronic phase has been accepted for filing and granted priority review by the FDA.

Zuplenz oral soluble film approved for nausea and vomiting

July 06, 2010

The FDA has approved Zuplenz (ondansetron oral soluble film, from Strativa) for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

Tasigna approved for the treatment of newly diagnosed chronic myeloid leukemia

June 18, 2010

Novartis announced that Tasigna (nilotinib) 150 mg capsules have been approved by the FDA for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase.

Phase 2 study of Telintra for myelodysplastic syndrome (MDS)

June 08, 2010

Telik Inc. announced positive results from its Phase 2 trial of Telintra (ezatiostat hydrochloride tablets, TLK199) in myelodysplastic syndrome (MDS) patients with an International Prognostic System Score (IPSS) of low to intermediate-1 risk.

Phase 2 study of ARQ 197 for non small cell lung cancer (NSCLC)

June 07, 2010

ArQule and Daiichi Sankyo announced the presentation of data from a Phase 2 trial showing encouraging overall survival (OS) results with ARQ 197 in combination with erlotinib among patients with advanced, refractory non-small cell lung cancer (NSCLC).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions